Arcus Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for late-stage development in clear cell renal cell carcinoma (ccRCC). Management also discussed an emerging inflammation and immunology (I&I) portfolio and provided 2026 financial guidance. Casdatifan data update ahead of ASCO GU CEO Terry Rosen and Chief Medical Officer Richard Markus emphasized Arcus's goal of establishing casdatifan as a “best-in-class” HIF-2a inhibitor for ccRCC. The company said updated results from the ARC-20 study will be presented at ASCO GU, including efficacy and biomarker data intended to further differentiate casdatifan from belzutifan, the only marketed HIF-2a inhibitor. ? Diamondback Sees Resilient Demand Despite Cautious Guidance MarketBeat Week in Review – 7/10 - 7/14 Markus said the updated analysis reflects a January 30 data cutoff from four late
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences (RCUS) had its price target raised by Citigroup Inc. from $44.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Arcus Biosciences (RCUS) had its price target raised by Leerink Partners from $36.00 to $49.00. They now have an "outperform" rating on the stock.MarketBeat
- Arcus Biosciences (RCUS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness Wire
RCUS
Earnings
- 2/25/26 - Beat
RCUS
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- RCUS's page on the SEC website